EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effects of GLP ‐1 Receptor Agonists on Paediatric Population in a Real World Setting

A G Barajas, Charles A Gagnon-Vargas, Jessica A Schmitt iD

Endocrinology, Diabetes & Metabolism · 2025

DOI: 10.1002/edm2.70053 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrinology, Diabetes & Metabolism, 2025. Verfasst von A G Barajas und 2 weiteren Autor:innen. Beteiligte Einrichtung: University of Alabama at Birmingham Marnix E. Heersink School of Medicine, Birmingham, Alabama, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Incidence of type 2 diabetes mellitus (T2DM) and obesity is increasing in children. We aimed to observe the metabolic health effects of glucagon‐like peptide 1 (GLP‐1) receptor agonists in paediatric patients with T2DM in a real‐world setting.

Methods

A retrospective chart review of patients aged 0 to 18 years with T2DM who were started on a GLP‐1 receptor agonist between August 2019 and August 2023 and followed for up to 24 months was included in this study.

Results

321 patients were included in the analysis. After 12 months of treatment with a GLP‐1 receptor agonist, haemoglobin A1c (HbA1c) was reduced by −1.04% ± 2.3% ( p < 0.001). At 24 months, HbA1c was similar to baseline (8.3% ± 2.5% vs. 7.9% ± 2.5%, p = 0.24). There was a significant ( p < 0.05) decrease in the use of metformin, basal insulin, and bolus insulin at one year which was sustained at the two‐year follow‐up for metformin ( p = 0.002). Overall, there was no significant change in BMI nor other metabolic parameters while undergoing treatment with a GLP‐1 receptor agonist.

Conclusion

Paediatric patients with T2DM using GLP‐1 receptor agonists experienced a significant decrease in HbA1c after 12 months of use, which was not sustained at 24 months. However, patients had a reduction in insulin and metformin use at 12 months. No significant impact was appreciated on BMI or other metabolic variables.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsHumansChildRetrospective StudiesFemaleAdolescentMaleChild, PreschoolInfantGlycated HemoglobinInfant, NewbornBlood GlucoseMetformin

Stichwörter der Autor:innen

adolescentdiabetes mellitusdrug utilisationglucagon‐like peptide‐1 receptor agoniststype 2

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsGlycated Hemoglobinhemoglobin A1c protein, humanBlood GlucoseMetformin

Autor:innen und Institutionen

  • University of Alabama at Birmingham Marnix E. Heersink School of Medicine, Birmingham, Alabama, USA.
  • Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, University of Alabama at Birmingham Marnix E. Heersink School of Medicine, Birmingham, Alabama, USA.

ORCID-Profile: Jessica A Schmitt

Förderung

  • NCATS NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Barajas, A. G., Gagnon-Vargas, C. A., & Schmitt, J. A. (2025). Effects of GLP ‐1 Receptor Agonists on Paediatric Population in a Real World Setting. Endocrinology, Diabetes & Metabolism. https://doi.org/10.1002/edm2.70053

Vancouver

Barajas AG, Gagnon-Vargas CA, Schmitt JA. Effects of GLP ‐1 Receptor Agonists on Paediatric Population in a Real World Setting. Endocrinology, Diabetes & Metabolism. 2025. doi:10.1002/edm2.70053

BibTeX
@article{Barajas2025,
  author = {Barajas, A G and Gagnon-Vargas, Charles A and Schmitt, Jessica A},
  title = {Effects of GLP ‐1 Receptor Agonists on Paediatric Population in a Real World Setting},
  journal = {Endocrinology, Diabetes & Metabolism},
  year = {2025},
  doi = {10.1002/edm2.70053}
}
Kostenlos starten →